Press Releases

May 14, 2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study Read More
May 8, 2019
Protagonist Therapeutics Reports First Quarter 2019 Financial Results Read More
May 8, 2019
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists Read More
May 7, 2019
Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019 Read More
April 1, 2019
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9 Read More
March 12, 2019
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Read More
March 5, 2019
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results Read More
February 21, 2019
Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28 Read More
January 16, 2019
Protagonist Therapeutics Reports Granting of Inducement Award Read More
January 9, 2019
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia Read More
January 7, 2019
Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology Read More
December 13, 2018
Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943 Read More
December 5, 2018
Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference Read More
November 27, 2018
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease Read More
November 7, 2018
Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14 Read More
November 6, 2018
Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update Read More
November 6, 2018
Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200 Read More
October 22, 2018
Protagonist Therapeutics Presents Clinical Data from the PROPEL Study of PTG-100 in Ulcerative Colitis at United European Gastroenterology Week Read More
October 8, 2018
Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting Read More
September 27, 2018
Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 Read More